CA3033253A1 - Composes d'aza-indazole destines a etre utilises dans des lesions de tendon et/ou de ligament - Google Patents

Composes d'aza-indazole destines a etre utilises dans des lesions de tendon et/ou de ligament Download PDF

Info

Publication number
CA3033253A1
CA3033253A1 CA3033253A CA3033253A CA3033253A1 CA 3033253 A1 CA3033253 A1 CA 3033253A1 CA 3033253 A CA3033253 A CA 3033253A CA 3033253 A CA3033253 A CA 3033253A CA 3033253 A1 CA3033253 A1 CA 3033253A1
Authority
CA
Canada
Prior art keywords
pyrazolo
pyridin
amino
chloro
benzenesulfonamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3033253A
Other languages
English (en)
Inventor
Badry Bursulaya
Andreas Fisch
James Paul LAJINESS
Rainer Machauer
Swapnil MALEKAR
Hank Michael James Petrassi
Farshad RAMAZANI
Anne-Catherine REMOND
Thomas Ullrich
Peggy USSELMANN
Eric Vangrevelinghe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA3033253A1 publication Critical patent/CA3033253A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention porte sur un composé de formule (I) sous forme libre ou sous forme de sel pharmaceutiquement acceptable (I), sur un procédé pour la fabrication du composé de l'invention et sur ses utilisations thérapeutiques. Cette invention concerne en outre une combinaison de principes pharmacologiquement actifs et une composition pharmaceutique.
CA3033253A 2016-09-23 2017-09-21 Composes d'aza-indazole destines a etre utilises dans des lesions de tendon et/ou de ligament Pending CA3033253A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662398865P 2016-09-23 2016-09-23
US62/398,865 2016-09-23
PCT/IB2017/055737 WO2018055551A1 (fr) 2016-09-23 2017-09-21 Composés d'aza-indazole destinés à être utilisés dans des lésions de tendon et/ou de ligament

Publications (1)

Publication Number Publication Date
CA3033253A1 true CA3033253A1 (fr) 2018-03-29

Family

ID=60164748

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3033253A Pending CA3033253A1 (fr) 2016-09-23 2017-09-21 Composes d'aza-indazole destines a etre utilises dans des lesions de tendon et/ou de ligament

Country Status (26)

Country Link
US (2) US10766894B2 (fr)
EP (1) EP3515913B1 (fr)
JP (1) JP7008065B2 (fr)
KR (1) KR102472017B1 (fr)
CN (1) CN109715629B (fr)
AU (1) AU2017332868B2 (fr)
BR (1) BR112019005318A2 (fr)
CA (1) CA3033253A1 (fr)
CL (1) CL2019000768A1 (fr)
CO (1) CO2019002618A2 (fr)
CR (1) CR20190144A (fr)
CU (1) CU24550B1 (fr)
DO (1) DOP2019000070A (fr)
EA (1) EA039908B1 (fr)
EC (1) ECSP19019613A (fr)
ES (1) ES2924104T3 (fr)
IL (1) IL264763B (fr)
JO (1) JOP20190053A1 (fr)
MX (1) MX388378B (fr)
MY (1) MY197464A (fr)
PE (1) PE20191006A1 (fr)
PH (1) PH12019500328A1 (fr)
RU (1) RU2758256C2 (fr)
SG (1) SG11201901249YA (fr)
WO (1) WO2018055551A1 (fr)
ZA (1) ZA201900861B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
JP7291077B2 (ja) 2016-12-16 2023-06-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｊａｋファミリーのキナーゼの低分子阻害物質
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
GB201813312D0 (en) 2018-08-15 2018-09-26 Modern Biosciences Ltd Compounds and their therapeutic use
EP3908279B1 (fr) 2019-01-11 2024-08-28 Novartis AG Inhibiteur de lta4h destiné au traitement ou à la prévention de l'hidrosadénite suppurée
AU2022233254A1 (en) 2021-03-11 2023-10-26 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1347972A1 (fr) 2000-12-19 2003-10-01 Smithkline Beecham Plc Pyrazolo 3,4-c]pyridine en tant qu'inhibiteurs de gsk-3
CA2514733A1 (fr) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a base d'un co-cristal
FR2871158A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
DE102004028862A1 (de) 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US9554319B2 (en) * 2005-09-27 2017-01-24 Qualcomm Incorporated Channel handoff methods in wireless broadcast systems
WO2008104473A2 (fr) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Inhibiteurs de kinase et procédés d'utilisation de ces derniers
BRPI0811065A2 (pt) 2007-06-08 2014-12-02 Abbott Lab Indazóis 5-heteroaril substituídos como inibidores de quinase
WO2010068287A2 (fr) 2008-12-11 2010-06-17 Angion Biomedica Corp. Modulateurs à petites molécules de l'activité du facteur de croissance (facteur de dispersion) des hépatocytes
EP2789614B1 (fr) 2009-08-11 2017-04-26 Bristol-Myers Squibb Company Azaindazoles comme modulateurs de la kinase Btk et son utilisation
US9556201B2 (en) * 2009-10-29 2017-01-31 Glaxosmithkline Llc Bicyclic pyridines and analogs as sirtuin modulators
JP2013542960A (ja) 2010-11-08 2013-11-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 脂肪酸シンターゼ阻害剤
WO2012158810A1 (fr) 2011-05-17 2012-11-22 Principia Biopharma Inc. Inhibiteurs de tyrosine kinase
UA112028C2 (uk) * 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
TWI629275B (zh) * 2013-03-13 2018-07-11 賽諾菲公司 Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途
CN105991238A (zh) 2015-03-06 2016-10-05 中兴通讯股份有限公司 信道状态信息的测量和反馈方法及发送端和接收端
WO2016161571A1 (fr) * 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Inhibiteurs de la btk de type indazole et azaindazole
HRP20211006T1 (hr) * 2016-09-23 2021-09-17 Novartis Ag Spojevi indazola za uporabu kod ozljeda tetiva i/ili ligamenata
JOP20190053A1 (ar) * 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط

Also Published As

Publication number Publication date
ECSP19019613A (es) 2019-03-29
WO2018055551A1 (fr) 2018-03-29
CO2019002618A2 (es) 2019-06-11
US10766894B2 (en) 2020-09-08
US20190300522A1 (en) 2019-10-03
BR112019005318A2 (pt) 2019-09-03
JP7008065B2 (ja) 2022-01-25
ES2924104T3 (es) 2022-10-04
CL2019000768A1 (es) 2019-05-24
RU2758256C2 (ru) 2021-10-27
IL264763B (en) 2021-05-31
PH12019500328A1 (en) 2019-11-11
KR102472017B1 (ko) 2022-11-28
CN109715629B (zh) 2022-04-12
AU2017332868A1 (en) 2019-03-07
AU2017332868B2 (en) 2020-02-13
CN109715629A (zh) 2019-05-03
MY197464A (en) 2023-06-19
RU2019111886A3 (fr) 2020-11-24
KR20190053224A (ko) 2019-05-17
US20210188842A1 (en) 2021-06-24
ZA201900861B (en) 2021-06-30
MX388378B (es) 2025-03-19
DOP2019000070A (es) 2019-05-15
CR20190144A (es) 2019-06-10
MX2019003373A (es) 2019-07-18
CU24550B1 (es) 2021-11-04
EP3515913A1 (fr) 2019-07-31
SG11201901249YA (en) 2019-04-29
JOP20190053A1 (ar) 2019-03-21
EA039908B1 (ru) 2022-03-25
JP2019529451A (ja) 2019-10-17
CU20190029A7 (es) 2019-11-04
PE20191006A1 (es) 2019-07-15
EA201990765A1 (ru) 2019-08-30
EP3515913B1 (fr) 2022-05-11
US11203595B2 (en) 2021-12-21
RU2019111886A (ru) 2020-10-23

Similar Documents

Publication Publication Date Title
US11203595B2 (en) Aza-indazole compounds for use in tendon and/or ligament injuries
CN110267945A (zh) 氰基取代的吲哚化合物及其作为lsd1抑制剂的用途
EP3389654A1 (fr) Composés d'arylsulfonamide à liaisons diamino-alkylamino ayant une activité sélective vis-à-vis des canaux sodiques voltage-dépendants
JP7494224B2 (ja) ビアリールジアルキルホスフィンオキシドｆｐｒ２アゴニスト
AU2017332867B2 (en) Indazole compounds for use in tendon and/or ligament injuries
WO2004060400A1 (fr) Recepteur antipsychotique du facteur de croissance epitheliale a ciblage moleculaire
HK40007808B (en) Aza-indazole compounds for use in tendon and/or ligament injuries
CA3033249C (fr) Composes d'indazole destines a etre utilises dans des lesions de tendon et/ou de ligament
JP2022532526A (ja) Ｈｂｖ感染又はｈｂｖ誘導性疾患の処置において有用なアミド誘導体
TW201041581A (en) N-[(7-azabicyclo[2.2.1]hept-1-yl)-aryl-methyl] benzamide derivatives, preparation thereof and therapeutic use thereof
EP4161916A1 (fr) Amides d'isoquinolinylméthyle substitués, analogues de ceux-ci et procédés les utilisant
BR112019005578B1 (pt) Compostos de indazol, seus usos, composição farmacêutica, e combinação
HK40007807B (en) Indazole compounds for use in tendon and/or ligament injuries
HK40007807A (en) Indazole compounds for use in tendon and/or ligament injuries
KR20260010408A (ko) Irak4의 리간드 지정 분해제로서의 헤테로아릴 화합물

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220920